Elise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, Joseph Fabrizio, Aditi Gupta, Jakub Svoboda, Stefan K Barta, Kristy M Walsh, Ellen B Napier, Rachel K Lundberg, Sunita D Nasta, James N Gerson, Daniel J Landsburg, Joyce Gonzalez, Andrew Gaano, Madison E Weirick, Christopher M McAllister, Moses Awofolaju, Gavin N John, Shane C Kammerman, Josef Novaceck, Raymone Pajarillo, Kendall A Lundgreen, Nicole Tanenbaum, Sigrid Gouma, Elizabeth M Drapeau, Sharon Adamski, Kurt D'Andrea, Ajinkya Pattekar, Amanda Hicks, Scott Korte, Harsh Sharma, Sarah Herring, Justine C Williams, Jacob T Hamilton, Paul Bates, Scott E Hensley, Eline T Luning Prak, Allison R Greenplate, E John Wherry, Stephen J Schuster, Marco Ruella, Laura A Vella
Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. SARS-CoV-2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic mRNA vaccine response in retrospective and prospective cohorts with lymphoma and CLL, paired with clinical and research immune parameters...
March 4, 2024: Journal of Infectious Diseases